Compensation award — excluded from discretionary-purchase analysis.
Traded Jun 1, 2026 · Filed Jun 3, 2026
MetLife's & Chief Risk Officer sold $1.74M of MetLife shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,738,823
Shares × reported transaction price
26 days after results of May 6, 2026, 65 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $81.84 on Jun 1, 2026, within 3% of its 52-week high, after a 5% rise over the previous 30 trading days
52-week range $67.70 (Mar 27, 2026) to $84.30 (May 21, 2026), 85% of the way up, from 251 adjusted closes. 30 trading days earlier: $78.08 on Apr 17, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.9% | -2.5% | +7.5% |
| 30 days | +8.4% | -0.8% | +9.2% |
| 90 days | +15.5% | +1.1% | +14.5% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.